Original Article

PROSTATE INTERNATIONAL

Prostate Int 2013;1(4):158-162 • http://dx.doi.org/10.12954/PI.13028

Can microfocal prostate cancer be regarded as low-risk prostate cancer?

Seung Hwan Lee, Kyu Hyun Kim, Jae Hyuk Choi, Kyo Chul Koo, Dong Hoon Lee, Byung Ha Chung

Department of Urology, Yonsei University Health System, Seoul, Korea

Purpose: Prostate specific antigen (PSA) screening for prostate cancer has become widespread, the prostate biopsy technique has evolved, and the occurrence of low-risk prostate cancer has been increasing. Even low-risk patients may demonstrate disease upgrading or upstaging. We aimed to evaluate the clinical importance of a single microfocal prostate cancer at biopsy in patients subsequently treated with radical prostatectomy.

Methods: A total of 337 cases of patients who underwent radical prostatectomy after prostate biopsies were retrospectively reviewed. Microfocal prostate cancer was defined as Gleason score 6 and a single positive core with ≤5% cancer involvement after the standard 12-core extended biopsy.

Results: Of the 337 prostatectomy specimens, 22 (6.5%) were microfocal prostate cancer based on prostate biopsy. On final pathology, microfocal patients were found to have significant 45% Gleason score upgrading ($P=0.02$) and 27% positive surgical margins ($P=0.04$) despite low PSA, compared with the nonmicrofocal prostate cancer group. Gleason upgrading was significantly higher in the microfocal prostate cancer group ($P=0.02$), whereas Gleason downgrading was significantly higher in the nonmicrofocal prostate cancer group ($P<0.01$). Furthermore, biochemical recurrence rate was no different between microfocal and nonmicrofocal prostate cancer at mean 31 months ($P=0.18$). Overall, 13 of 22 cases (53.1%) in the microfocal prostate cancer group showed Gleason upgrading or stage upgrading.

Conclusions: Based on higher rates of Gleason score upgrading or stage upgrading cases in microfocal prostate cancer group, compared with nonmicrofocal prostate cancer group, active surveillance should be cautiously applied to these patients.

Keywords: Prostate neoplasms, Biopsy, Low-risk prostate cancer, Prostatectomy

INTRODUCTION

Prostate specific antigen (PSA) screening for prostate cancer has become widespread, the prostate biopsy technique has evolved, and the detection of low-risk prostate cancer has been increasing [1]. Concerns have been expressed that the increased detection of indolent prostate cancer leads to patients receiving unnecessary treatment and dealing with unnecessary side effects [2].

Patients diagnosed with Gleason score (GS) 6 microfocal prostate cancer are often considered to have low-risk disease during initial counseling [3]. However, according to the Epstein criteria [4], the preoperative diagnosis of low-risk prostate cancer is a difficult decision to make since prostate cancer is a multifocal, heterogeneous disease. Some studies have reported that even low-risk patients may demonstrate disease upgrading or upstaging [5].

A strong connection between microfocal prostate cancer at biopsy and clinically insignificant disease would be a strong argument against treating these patients [6]. We aimed to evaluate the clinical importance of single microfocal prostate cancer (GS ≤ 6) at biopsy in patients subsequently treated with

Corresponding author: Byung Ha Chung
Department of Urology, Gangnam Severance Hospital, Yonsei University Health System, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea
E-mail: chung646@yuhs.ac / Tel: +82-2-2019-3474 / Fax: +82-2-3462-8887
Submitted: 8 October 2013 / Accepted after revision: 26 November 2013

http://p-international.org/
pISSN: 2287-8882 • eISSN: 2287-903X

radical prostatectomy (RP). We characterized pathological stage, surgical margin, tumor volume, and PSA density in men with low-risk cancer and identified pretreatment clinical parameters that may predict pathological outcomes.

MATERIALS AND METHODS

1. Patients and procedure

The study was approved by the Institutional Review Board of our institution. From January 2002 to September 2012, 337 cases that underwent RP after 12-core extended prostate biopsies were retrospectively reviewed. Microfocal prostate cancer was defined as GS 6 and a single positive core with ≤5% cancer involvement after the 12-core biopsy. We excluded patients who had undergone prostate biopsy at another institution, hormone therapy, or radiation therapy before the RP.

In all patients, serum PSA levels were obtained before digital rectal examination and transrectal ultrasonography. Clinical staging was performed according to the TNM staging system, and the ellipsoid formula was used to derive prostate volume via transrectal ultrasonography. All biopsy and RP specimens were reviewed by a single genitourinary pathologist. All biopsy cores were individually labeled. For each biopsy protocol, the number of cores involved by cancer, total length of tissue sampled, total length of cancer detected, and GS were determined.

Patient age, preoperative PSA level, and clinical stage were recorded in all patients. The RP was performed by a single surgeon (B.H.C.). Lymph node dissection was selectively performed in patients with clinical stage T3 or greater. Pathological grade and stage were defined, and surgical margin status was noted following light microscopy examination of the specimen slides. The prostatectomy specimens were fixed overnight in 10% neutral buffered formaldehyde and coated with India ink. Transverse whole mount step section specimens were obtained with 4-mm intervals on a plane parallel to that in which transverse T2-weighted sequences were performed. Upstaging was defined as pathological stage T3a, T3b, and T4. Patients were followed postoperatively at every 3 months for the first year and every 6 months afterward with serum PSA measurement. We define biochemical recurrence as PSA greater than 0.2 ng/mL.

2. Statistical analysis

Statistical analyses were performed using Student *t*-test to evaluate the demographic and clinical differences between microfocal prostate cancer and nonmicrofocal prostate cancer groups. The Mann-Whitney *U* test was used to compare the microfocal tumor characteristics, including biopsy location, as well as pathologic findings between the disease upgrading or upstaging group and the other group. All *P*-values less than 0.05 were considered statistically significant. The Kaplan-Meier method was used to compare biochemical recurrence-free survival between microfocal prostate cancer and nonmicrofocal prostate cancer. All statistical analyses were performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA).

RESULTS

Of the total 337 RP cases, 22 patients were diagnosed with microfocal prostate cancer upon biopsy. Mean age was comparable between both groups, and mean PSA and GS were 5.6 ng/mL and 5.8, respectively, in the microfocal prostate cancer group and 13.2 ng/mL and 7.1, respectively (Table 1). PSA density in the microfocal prostate cancer group was significantly lower than in nonmicrofocal prostate cancer group

Table 1. Patient characteristics and pathological outcome

Characteristic	Microfocal PCa	Nonmicrofocal PCa	*P*-value
Number	22	315	
Age (yr)	63.6±7.0 (49–71)	63.5±5.8 (48–74)	0.49
PSA (ng/mL)	5.6±2.6 (2.5–11.3)	13.2±3.8 (3.2–21.7)	0.02
PSA density (ng/mL)	0.18±0.09 (0.07–0.37)	0.36±0.07 (0.10–0.78)	0.01
Prostate volume (mL)	30.2±10.5 (16.4–64.5)	36.7±11.4 (14.8–121.3)	0.48
Gleason score, mean (range)	5.8 (4–6)	7.1 (5–9)	<0.01
Pathology, n (%)			
PSM	6 (27.2)	45 (14.3)	0.04
GS upgrading	10 (45.4)	69 (21.9)	0.02
GS downgrading	1 (4.5)	101 (32.1)	<0.01
Stage upgrading	11 (50.0)	152 (48.3)	0.55
Biochemical recurrence	3 (13.6)	56 (17.6)	0.18

Values are presented as mean±standard deviation (range) unless otherwise indicated.
PCa, prostate cancer; PSA, prostate specific antigen; PSM, positive surgical margin; GS, Gleason score.